MaaT Pharma To present preclinical data on MaaT034 at AACR

MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of lead product MaaT013 (donor dependent) in combination with checkpoint inhibitors in metastatic melanoma expected in 2H25 could further highlight the potential for microbiome therapies to improve checkpoint inhibitor outcomes in the solid tumour setting, potentially expanding MaaT's commercial opportunity. We reiterate our € 17 TP and Buy rating.